Wockhardt's Investigational Antibiotic Zaynich Successfully Treats Cancer Patient with Drug-Resistant Infection in US

Wockhardt Limited has announced the successful use of its investigational antibiotic, Zaynich (Zidebactam/Cefepime- WCK 5222), to treat a young immune-compromised cancer patient in the US with a chronic bilateral thigh infection caused by an extreme-drug resistant Pseudomonas. The patient, who had been hospitalized for nearly 9 months, was successfully treated with 4 weeks of Zaynich under compassionate use, enabling doctors to resume chemotherapy. This marks the first instance in the US where Zaynich has been used to combat a complex infection caused by extreme-drug resistant Pseudomonas. The patient had a complicated clinical history and the infecting pathogen was a metallo-B-lactamase-harbouring Pseudomonas aeruginosa, one of the toughest resistance mechanisms known. Zaynich is currently undergoing a multi-national Phase 3 study which is expected to support its registration/marketing authorization globally.